ADE LLC’s AbbVie ABBV Stock Holding History

ADE LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-33	Closed	-$4K	–	260
2021 Q1	$4K	Hold	33	–	–	﹤0.01%	212
2020 Q4	$4K	Buy	+33	New	+$3.17K	﹤0.01%	294

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

ADE LLC's ABBV Position: Q2 2021 in Review

ADE LLC sold out of AbbVie (ABBV) in Q2 2021, closing a stake of 33 shares — an estimated $4K sold.

ADE LLC first reported a position in ABBV in Q4 2020 and held it in 2 quarters. The position peaked at $4K in Q1 2021. 2,676 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.

ADE LLC reported no remaining AbbVie position as of Q2 2021 after selling out during the quarter.
ADE LLC sold 33 AbbVie shares in Q2 2021, an estimated $4K.
ADE LLC first reported a position in AbbVie in Q4 2020 and held it in 2 quarters.
ADE LLC's AbbVie position peaked at $4K in Q1 2021.
2,676 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.

Based on ADE LLC's 13F filing for Q2 2021, filed 27 Jul 2021.